tazarotene

FDA Drug Profile — TAZORAC, Arazlo, TAZAROTENE, tazarotene, Tazorac

tazarotene is listed in the FDA National Drug Code directory with 14 NDC codes, marketed under brand names including TAZORAC, Arazlo, TAZAROTENE. Available dosage forms: cream, lotion, gel, aerosol, foam.

Drug details

Generic Name
tazarotene
Brand Names
TAZORAC, Arazlo, TAZAROTENE, tazarotene, Tazorac, FABIOR
Application Number
NDA021184
Sponsor
Almirall, LLC
NDC Codes
14
Dosage Forms
CREAM, LOTION, GEL, AEROSOL, FOAM
Routes
CUTANEOUS, TOPICAL
Active Ingredients
TAZAROTENE

Indications and Usage

1 INDICATIONS AND USAGE Trilitas™ gel, 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement. ( 1.1 ) Trilitas™ gel, 0.1% is indicated for the topical treatment of mild to moderate facial acne vulgaris. ( 1.2 ) Limitations of Use The safety of Trilitas™ gel use on more than 20% body surface area has not been established. ( 1.3 ) 1.1 Plaque Psoriasis Trilitas™ (tazarotene) gel, 0.1% is indicated for the topical treatment of patients with plaque psoriasis of up to 20% body surface area involvement. 1.2 Acne Vulgaris Trilitas™ (tazarotene) gel, 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate severity. The efficacy of Trilitas™ gel in the treatment of acne previously treated with other retinoids or resistant to oral antibiotics has not been established. 1.3 Limitations of Use The safety of Trilitas™ gel use on more than 20% body surface area has not been established in psoriasis or acne [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ].

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.